about
Sustainable intensification in agricultural systems.Ethnic differences in prediabetes and diabetes in the Suriname Health Study.The architecture of risk for type 2 diabetes: understanding Asia in the context of global findings.Complications in Advanced Diabetics in a Tertiary Care Centre: A Retrospective Registry-Based StudyPilot evaluation of an integrated monitor-adhesive patch for long-term cardiac arrhythmia detection in India.Replication of type 2 diabetes candidate genes variations in three geographically unrelated Indian population groups.Association of TCF7L2 gene polymorphisms with T2DM in the population of Hyderabad, India.The economic burden of diabetes in India: a review of the literatureIsothiocyanate-rich Moringa oleifera extract reduces weight gain, insulin resistance, and hepatic gluconeogenesis in mice.Fetal Sex Modulates Developmental Response to Maternal MalnutritionA case for new therapy for diabetes, is it leptin?Should depressive patients undergo a regular diabetes screening test?Meeting the challenges of stroke in India.Reporter protein complementation imaging assay to screen and study Nrf2 activators in cells and living animals.Risk factors of type 2 diabetes in population of Jammu and Kashmir, India.Challenges constraining access to insulin in the private-sector market of Delhi, IndiaDesigning breathalyser technology for the developing world: how a single breath can fight the double disease burden.Revisiting "Vegetables" to combat modern epidemic of imbalanced glucose homeostasisInternational Models of Care that Address the Growing Diabetes Prevalence in Developing Countries.Mitigating regulatory impact: the case of partial price controls on metformin in India.Globalization and Food Prestige among Indian Adolescents.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Punjab cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bangalore cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Andhra Pradesh cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Maharashtra cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the East India cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Gujarat cohort of the A1chieve studyClinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the West Bengal cohort of the A1chieve studyClinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Chennai cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kerala cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the South India cohort of the A1chieve studyClinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North India cohort of the A1chieve studyClinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Delhi cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Tamil Nadu cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve studyClinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Karnataka cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Hyderabad cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Haryana cohort of the A1chieve study.Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rajasthan cohort of the A1chieve study.
P2860
Q28607323-29051644-B9E1-4B9A-9C98-90D411A0E018Q29353609-278007C1-3BCD-4670-83DE-5326A118FA7BQ30361503-EA7A63B3-8105-44FA-B246-5364A338E8FEQ30384040-DC1BFBAC-C0B6-4A1E-97E1-4731EFCCBBC3Q33163610-B4DA01BC-CD2D-4F61-8B33-5E08745B9CD4Q34634363-024484FC-C345-4ECB-B410-643E54E653E9Q34663674-6A096BA8-7E7E-46DB-91FA-F702FB195F58Q34789055-0EE3D72D-EE75-4C88-97A1-11F24E6DA719Q35685308-62D5D437-AEEB-45EB-B970-F7DC6E3550C2Q36257663-97C26B8D-FC8C-49E4-A3CA-76313E4D5B2FQ36700857-1BAE73A1-CFE3-420C-81A6-BCFE4B7253CFQ37016075-1762D529-13D4-4FB2-BAA3-1ADD12B87FE3Q37039693-B9358BBE-645A-45CF-9463-96302E63A679Q37139342-0B3BD759-7B12-4E13-8611-AB75BC2D3AD6Q37199202-A6E1C0E4-9CB2-474D-A3A3-49EFF2FE5983Q37659857-71E14BF0-BDDC-49C8-89F2-C9FD5B13625CQ38195653-984A8BB0-B3D2-48A6-A090-AD254E9F9B6CQ38225855-4A06AA58-3F14-481A-ADAD-FE536B45B58FQ38379522-5EEB53A5-C7B8-4D83-BB56-F24FCAF24CCDQ38957835-B9CDD70C-E470-4BC7-81EF-94EECA010E5AQ40691822-39D6B8BA-7137-4127-875F-78C22E339AB2Q41815301-0C68C4CE-01AC-4E29-AA98-FF94690997B2Q41817369-8FA402D3-30AC-4F5B-A64E-B6B8063828EAQ41866965-7D907894-3FB2-4D67-BB60-612547EF3AF6Q41873306-49E38C60-4DF6-4C93-9D2A-B2F619430227Q41896688-4B425CF6-F5F4-4698-80AF-6B1521EC7C9FQ41947217-B7D2C085-86C1-49E9-871D-0F7EC60713EBQ42042988-AC7AC15E-40CC-4FF9-9012-7953E94A618AQ42070613-6E4BB866-DA87-4890-BEDA-538A65F651ADQ42084063-B7A98C56-C176-428B-93B1-E8AFE555FFE3Q42096791-C396767C-7636-4296-ABD0-EC9A1F6A0A5DQ42136798-B471427F-8A95-478B-931B-FA754C19BA55Q42245206-3B665CC0-524C-4BC3-9D45-21ABCE03CCCCQ42775769-6D45A3A5-5114-4E03-A5FE-0DFD1F9B29DEQ42775773-E62FB977-16B2-43F2-84B4-3A5C8F0A0EE3Q42775774-55C8F968-9E26-4C92-95BE-8A79509D861AQ42775782-92137A05-8A61-4317-BFB4-858DE0ED0BF4Q42775787-EFAAAAC5-8BB0-4E1C-9765-D72E18CFF5D6Q42775789-C6BF1CCB-34A9-4BF5-939D-A92469C16955Q42775792-A30E725E-92C7-457F-B2E5-10119269B28F
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Public health: India's diabetes time bomb.
@en
type
label
Public health: India's diabetes time bomb.
@en
prefLabel
Public health: India's diabetes time bomb.
@en
P2860
P356
P1433
P1476
Public health: India's diabetes time bomb.
@en
P2093
Priya Shetty
P2860
P2888
P356
10.1038/485S14A
P407
P577
2012-05-01T00:00:00Z
P5875
P6179
1043793653